Large safety check for approved lung cancer drug
NCT ID NCT03844464
Summary
This study monitored the safety of Lorbrena, an approved lung cancer medication, in real-world patients after it became available. It tracked 1,290 patients with non-small cell lung cancer to better understand side effects, specifically focusing on brain-related issues and liver problems. The goal was to gather more safety information from regular clinical use to help doctors and patients manage treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
3-22-7, Yoyogi, Shibuya-ku
Tokyo, 151-8589, Japan
Conditions
Explore the condition pages connected to this study.